FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S.
Read MoreThe twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S.
Read MoreThe FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's
Read MoreSwiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.
Read MoreThe results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
Read MoreDemand for Eli Lilly's Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily
Read MoreAstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant
Read MoreLeqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
Read MoreSesame is offering compounded semaglutide — the active ingredient in Wegovy and Ozempic — to help users access obesity and
Read MoreThe late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period. Source
Read More